FeesSafety
Pluang+

nCino boosts buyback by $100M as AI-driven revenue and profits rise in Q2

Company Fundamentals
03 Sep 2026
PYMNTS
View Source
Bullish
nCino boosts buyback by $100M as AI-driven revenue and profits rise in Q2

nCino reported an 8% revenue increase to $161 million and improved profitability in its fiscal Q2, driven by strong demand for its AI capabilities. The company authorized an additional $100 million for share repurchases, bringing total buybacks since April 2025 to $300 million. CEO Sean Desmond highlighted growing customer consolidation on nCino's platform and expanded AI commitments, with renewals from major U.S. clients and new international customers. For fiscal 2027, nCino projects revenue near $645 million and expects to fund buybacks through cash, credit, or future cash flows.

More News

Dayton T. Brown opens new Huntsville Test & Qualification Center to boost aerospace and defense testing.

Dayton T. Brown opens new Huntsville Test & Qualification Center to boost aerospace and defense testing.

Dayton T. Brown, Inc. inaugurated its new 104,000-square-foot Test & Qualification Center in Huntsville, Alabama, enhancing its capacity to support aerospace, defense, and propulsion programs. The facility's strategic location near Huntsville's aeros...

Market News
Bullish
43 minutes ago
60% of CCOs say communications functions lag behind their leadership roles, needing better systems and resources.

60% of CCOs say communications functions lag behind their leadership roles, needing better systems and resources.

A new study by The Grossman Group reveals that while 60% of chief communications officers (CCOs) have influence at the leadership level, their communications functions lack the necessary systems, skills, and AI capabilities to fully meet their mandat...

Others
Neutral
43 minutes ago
Over 200 companies advance 240+ Alzheimer's drugs, marking a new phase in treatment development

Over 200 companies advance 240+ Alzheimer's drugs, marking a new phase in treatment development

More than 200 companies are actively developing over 240 Alzheimer's disease therapies, with around 20 drugs in late-stage trials and many others in earlier phases. Key players include Eli Lilly, Biogen, Johnson & Johnson, and Eisai, focusing on inno...

Market News
Bullish
43 minutes ago
Sagimet Biosciences starts key Phase 3 trial for acne drug denifanstat in the U.S.

Sagimet Biosciences starts key Phase 3 trial for acne drug denifanstat in the U.S.

Sagimet Biosciences has initiated a crucial Phase 3 clinical trial in the U.S. for denifanstat, an oral treatment targeting moderate to severe acne. The trial, named AURORA, aims to enroll around 800 patients, including adolescents, to support regula...

Market News
Bullish
1 hour ago
Nokia beats Q3 earnings and revenue estimates with strong AI and cloud sales growth.

Nokia beats Q3 earnings and revenue estimates with strong AI and cloud sales growth.

Nokia reported third-quarter 2026 earnings per share of $0.10, surpassing the $0.08 estimate, and revenue of $5.78 billion, exceeding the $5.72 billion forecast. The company's AI and cloud sales surged 123%, driven by high demand for its IP Networks ...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App